Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561391 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT01561391 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 36 participants.
The verdict
NCT01561391, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
This trial is conducted in North America. The aim of this trial is to compare the safety and efficacy of activated recombinant human factor VII in patients with haemophilia A or B undergoing major surgical procedures.
Interventions
- DRUG activated recombinant human factor VII
- OTHER factor IX
- DRUG factor VIII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1998-04 |
| Est. Completion | 2004-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01561391
The ClinicalTrials.gov registry entry for NCT01561391 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which activated recombinant human factor VII is the first listed.
NCT01561391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01561391 about?
NCT01561391 is a clinical study titled "Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery". This trial is conducted in North America. The aim of this trial is to compare the safety and efficacy of activated recombinant human factor VII in patients with haemophilia A or B undergoing major surgical procedures.
What is the current status of trial NCT01561391?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 1998-04. Estimated completion is 2004-05.
What interventions are being tested in trial NCT01561391?
The interventions under investigation include: activated recombinant human factor VII (DRUG), factor IX (OTHER), factor VIII (DRUG).
Who is sponsoring clinical trial NCT01561391?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.